Literature DB >> 16116122

Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine.

D M Ficker1, M Privitera, G Krauss, A Kanner, J L Moore, T Glauser.   

Abstract

The authors conducted a 3-month, prospective, open-label study assessing the effects of switching from immediate-release carbamazepine formulations to an equal total daily dose of carbamazepine extended-release capsules (CBZ-ERC) in adolescents and adults with epilepsy. Using validated, epilepsy-specific measures the authors found that switching to CBZ-ERC significantly improved patients' adverse events and quality-of-life measures. Switching to CBZ-ERC also improved seizure control.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16116122     DOI： 10.1212/01.wnl.0000172932.95985.51

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  13 in total

1.  Monotherapy in newly diagnosed epilepsy: levetiracetam versus standard anticonvulsants.

Authors:  Mohamad Z Koubeissi
Journal:  Epilepsy Curr       Date:  2014-09       Impact factor: 7.500

2.  Assessing bioequivalence of generic modified-release antiepileptic drugs.

Authors:  Emily L Johnson; Yi-Ting Chang; Barbara Davit; Barry E Gidal; Gregory L Krauss
Journal:  Neurology       Date:  2016-03-25       Impact factor: 9.910

3.  Generic antiepileptic drugs: current controversies and future directions.

Authors:  Michael D Privitera
Journal:  Epilepsy Curr       Date:  2008 Sep-Oct       Impact factor: 7.500

Review 4.  Designing clinical trials to assess antiepileptic drugs as monotherapy : difficulties and solutions.

Authors:  Emilio Perucca
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 5.  Extended-release formulations for the treatment of epilepsy.

Authors:  Meir Bialer
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

6.  Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials.

Authors:  Richard H Weisler; Robert Hirschfeld; Andrew J Cutler; Thomas Gazda; Terence A Ketter; Paul E Keck; Alan Swann; Amir Kalali
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 7.  A Clinician's Guide to Oral Extended-Release Drug Delivery Systems in Epilepsy.

Authors:  James W Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Jul-Aug

8.  [Slow release versus immediate release oxcarbazepine in difficult-to-treat focal epilepsy: a multicenter, randomized, open, controlled, parallel group phase III study].

Authors:  B J Steinhoff; H Stefan; A Schulze-Bonhage; R Hueber; W Paulus; M Wangemann; C E Elger
Journal:  Nervenarzt       Date:  2012-10       Impact factor: 1.214

9.  New-onset partial epilepsy in adults.

Authors:  Lynn Liu; J Craig Henry
Journal:  Curr Treat Options Neurol       Date:  2009-07       Impact factor: 3.598

10.  Managing patient adherence and quality of life in epilepsy.

Authors:  Joanne Eatock; Gus A Baker
Journal:  Neuropsychiatr Dis Treat       Date:  2007-02       Impact factor: 2.570
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.